0.124 billion USD! FOSUN PHARMA and United Family Healthcare "completely part ways" | Quick announcement.

① FOSUN PHARMA's subsidiary plans to sell a 6.6% stake in the symbol company for 0.124 billion USD; ② The relationship between FOSUN PHARMA and Huameijia can be traced back to 2009; ③ After this Trade is completed, FOSUN PHARMA will completely exit Huameijia.

cls.cnMar 13 11:26 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

It was reported that FOSUN PHARMA will sell its Indian pharmaceutical company, and it stated that it will continue to promote the development of the Indian company in the Global market.

① It is rumored that FOSUN PHARMA will sell its pharmaceutical company Gland Pharma located in India, and the company stated it will continue to promote Gland Pharma's development and growth in the Global market. ② Previously, FOSUN PHARMA had reduced its Shareholding in Gland Pharma to supplement working capital, repay interest-bearing debts, and so on.

cls.cnFeb 20 18:46 ET

Q3 earnings have increased year-on-year, fosun pharma promotes the sales of botulinum toxin products domestically | Direct coverage of the earnings conference.

①At the earnings conference, fosun pharma indicated that due to the continued expansion of innovative drugs and other factors, the company's performance in Q3 improved year-on-year. ② Chief financial officer Chen Zhanyu revealed that the company is actively promoting the prompt market entry of injectable type A botulinum toxin in china. ③ The privatization process of henlius and the accessibility of CAR-T products have also attracted significant attention.

cls.cnNov 13, 2024 08:52 ET

Vitamin price increase dividend realized! zhejiang nhu Q3 net profit increased by nearly 190% year-on-year|interpretations

1. Zhejiang NHU and Zhejiang Garden Biopharmaceutical have seen a sharp increase in profits in Q3; 2. The rise in prices of vitamins has boosted manufacturers' performance; 3. Vitamin prices have declined from their peak, but still remain relatively high; 4. The price hike benefits will continue into Q4, but profit growth may slow down.

cls.cnOct 23, 2024 09:04 ET

Zhejiang Hisun Pharmaceutical: Give up the pharmaceutical distribution raw material business, leading to a decline in H1 revenue. Sales of Olsalazine increased significantly compared to the same period last year.

①At the earnings conference, the CFO of Zhejiang Hisun Pharmaceutical explained that the decline in H1 revenue was due to the company's abandonment of low-margin pharmaceutical distribution raw material business and other factors. ②President Xiao Weihong addressed questions about the growth in endocrine drug revenue and the future business model of the animal health sector.

cls.cnSep 4, 2024 09:29 ET